CorMedix Inc. (CRMD)

CorMedix is no longer a pre-revenue biotech: recent SEC filings show a profitable commercial anti-infectives business (DefenCath plus the Melinta portfolio) with strong liquidity and cash generation. Current multiples are very low (P/E ~3.4, EV/EBITDA ~2.1) and balance-sheet risk looks manageable, but investors are being asked to underwrite reimbursement-policy risk (TDAPA step-down beginning July 2026), acquisition integration, and remediation of a material internal-control weakness; discounted-cash-flow outputs also point to downside, so this is attractive but not low-risk.

A market-rewarded Q2 print (revenue $101.9M, FY26 adjusted-EBITDA guidance raised to $125–140M, analyzer score +0.6) is digesting into a positive-but-cooling tape (in-window aggregate ≈ +0.18, price fading from $8.43 to ~$7.96), with the next named driver an expected REZZAYO sNDA filing (announced, date TBD) and the post-TDAPA reimbursement transition still under watch. The sentiment delta is determinate at item level — flat-to-cooling within positive territory (baseline aggregate under-sampled at one scored item) — retail is indeterminate, and the Red-Flag Screen is clean, leaving a mixed/forming setup driven by a trailing, partially-priced catalyst set.

Score 2 (mostly neutral/weak bearish, bounce-only): price under SMA20/50/200 and EMA9/21 with MACD below zero and below signal, RSI 41.9 sub-50, ADX 18.7 weak; only Williams %R (-91.5) is oversold. The trend-alignment gate rejects any pullback/oversold limit (countertrend), and no momentum breakout exists; liquidity and calendar checks all pass but the chart offers no tradeable bullish setup.